https://wikimd.org/index.php?action=history&feed=atom&title=XEN-D0101XEN-D0101 - Revision history2026-04-27T02:13:41ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=XEN-D0101&diff=5369451&oldid=prevPrab: CSV import2024-03-06T06:41:04Z<p>CSV import</p>
<p><b>New page</b></p><div>[[File:XEN-D0101.svg|thumb|{{PAGENAME}}]]<br>'''XEN-D0101''' is a potent and selective small molecule inhibitor of the [[voltage-gated sodium channel]] Nav1.7, which is being developed by [[Xenon Pharmaceuticals]] for the treatment of [[pain]]. <br />
<br />
== Mechanism of Action ==<br />
XEN-D0101 works by blocking the Nav1.7 sodium channel, which is a key player in the generation and conduction of pain signals. This channel is highly expressed in [[nociceptive neurons]], which are the nerve cells responsible for sensing pain. By blocking this channel, XEN-D0101 can effectively reduce the transmission of pain signals, thereby providing relief from pain.<br />
<br />
== Clinical Development ==<br />
XEN-D0101 has undergone Phase 1 and Phase 2 clinical trials for the treatment of various types of pain, including [[neuropathic pain]], [[inflammatory pain]], and [[visceral pain]]. The results from these trials have shown that XEN-D0101 is well-tolerated and has a favorable safety profile. In addition, some trials have shown promising efficacy results, with patients reporting significant reductions in pain intensity.<br />
<br />
== Potential Applications ==<br />
Given its mechanism of action, XEN-D0101 has the potential to be used in the treatment of a wide range of pain conditions. These include conditions that are currently difficult to treat with existing therapies, such as [[chronic pain]] conditions and certain types of [[neuropathic pain]]. In addition, because XEN-D0101 is a selective inhibitor of Nav1.7, it is expected to have fewer side effects than non-selective sodium channel blockers.<br />
<br />
== Future Directions ==<br />
Further clinical development of XEN-D0101 is ongoing, with additional trials planned to further evaluate its safety and efficacy in various pain conditions. If these trials are successful, XEN-D0101 could represent a significant advancement in the treatment of pain, providing a new option for patients who are not adequately managed with current therapies.<br />
<br />
[[Category:Drugs]]<br />
[[Category:Pain management]]<br />
[[Category:Clinical trials]]<br />
[[Category:Pharmacology]]<br />
{{pharmacology-stub}}<br />
{{drug-stub}}</div>Prab